MX2017013154A - Conjugados anticuerpo-farmaco de sitio especifico. - Google Patents
Conjugados anticuerpo-farmaco de sitio especifico.Info
- Publication number
- MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A MX 2017013154 A MX2017013154 A MX 2017013154A
- Authority
- MX
- Mexico
- Prior art keywords
- site
- specific antibody
- drug conjugates
- amino acid
- antibody
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 2
- 235000001014 amino acid Nutrition 0.000 abstract 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 abstract 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 abstract 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000562 conjugate Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 235000018417 cysteine Nutrition 0.000 abstract 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 abstract 1
- 125000006239 protecting group Chemical group 0.000 abstract 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506393.6A GB201506393D0 (en) | 2015-04-15 | 2015-04-15 | Site-specific antibody-drug conjugates |
| PCT/EP2016/058371 WO2016166299A1 (en) | 2015-04-15 | 2016-04-15 | Site-specific antibody-drug conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013154A true MX2017013154A (es) | 2018-02-21 |
Family
ID=53333825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013154A MX2017013154A (es) | 2015-04-15 | 2016-04-15 | Conjugados anticuerpo-farmaco de sitio especifico. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180125994A1 (OSRAM) |
| EP (1) | EP3283118A1 (OSRAM) |
| JP (1) | JP2018511628A (OSRAM) |
| KR (1) | KR20170137115A (OSRAM) |
| CN (1) | CN107683146A (OSRAM) |
| AU (1) | AU2016249877A1 (OSRAM) |
| BR (1) | BR112017022256A2 (OSRAM) |
| CA (1) | CA2981920A1 (OSRAM) |
| GB (1) | GB201506393D0 (OSRAM) |
| MX (1) | MX2017013154A (OSRAM) |
| WO (1) | WO2016166299A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3579883T3 (pl) | 2017-02-08 | 2022-01-24 | Adc Therapeutics Sa | Koniugaty pirolobenzodiazepina-przeciwciało |
| ES2871001T3 (es) | 2017-02-08 | 2021-10-28 | Adc Therapeutics Sa | Conjugados de pirrolobenzodiazepinas y anticuerpos |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| WO2018192944A1 (en) | 2017-04-18 | 2018-10-25 | Medimmune Limited | Pyrrolobenzodiazepine conjugates |
| EP3612235A1 (en) * | 2017-04-20 | 2020-02-26 | ADC Therapeutics SA | Combination therapy with an anti-psma antibody-drug conjugate |
| JP7402691B2 (ja) | 2017-04-20 | 2023-12-21 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ２５抗体薬物複合体による併用療法 |
| JP2020523384A (ja) | 2017-06-14 | 2020-08-06 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ２５ ａｄｃを投与するための投与レジメ |
| SG11202000358YA (en) | 2017-08-18 | 2020-02-27 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| WO2020127573A1 (en) | 2018-12-19 | 2020-06-25 | Adc Therapeutics Sa | Pyrrolobenzodiazepine resistance |
| GB201820725D0 (en) | 2018-12-19 | 2019-01-30 | Adc Therapeutics Sarl | Pyrrolobenzodiazepine resistance |
| MX2021010477A (es) | 2019-03-15 | 2021-10-01 | Medimmune Ltd | Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer. |
| PH12021552363A1 (en) * | 2019-03-29 | 2022-09-05 | Medimmune Ltd | Compounds and conjugates thereof |
| GB201908128D0 (en) | 2019-06-07 | 2019-07-24 | Adc Therapeutics Sa | Pyrrolobenzodiazepine-antibody conjugates |
| TW202140076A (zh) * | 2020-01-22 | 2021-11-01 | 英商梅迪繆思有限公司 | 化合物及其軛合物 |
| GB202011993D0 (en) | 2020-07-31 | 2020-09-16 | Adc Therapeutics Sa | ANTI-IL 13Ra2 antibodies |
| PE20240727A1 (es) * | 2021-08-27 | 2024-04-15 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos |
| CN116370651A (zh) * | 2023-04-04 | 2023-07-04 | 上海愿智生物技术有限公司 | 一种抗psma抗体-药物缀合物及其制备方法和应用 |
| WO2025145034A1 (en) * | 2023-12-29 | 2025-07-03 | T.O.A.D. Oncology Sa | Anti-psma conjugates and methods of using the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20003099A3 (cs) * | 1998-02-25 | 2002-04-17 | Lexigen Pharmaceuticals Corporation | Zvýąení doby poloviční ľivotnosti cirkulujících fúzních proteinů odvozených od protilátek |
| EP1817341A2 (en) * | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| EP2543730B1 (en) * | 2010-03-04 | 2018-10-31 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| JP6014596B2 (ja) * | 2010-11-09 | 2016-10-25 | メディミューン，エルエルシー | 均一コンジュゲーションのための抗体足場 |
| EP2906250B1 (en) * | 2012-10-12 | 2018-05-30 | ADC Therapeutics SA | Pyrrolobenzodiazepine-anti-psma antibody conjugates |
| SI2906253T1 (sl) * | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin-protitelo proti PSMA |
| CN105873612A (zh) * | 2013-08-28 | 2016-08-17 | 施特姆森特克斯股份有限公司 | 改造的抗-dll3缀合物以及应用方法 |
-
2015
- 2015-04-15 GB GBGB1506393.6A patent/GB201506393D0/en not_active Ceased
-
2016
- 2016-04-15 AU AU2016249877A patent/AU2016249877A1/en not_active Abandoned
- 2016-04-15 WO PCT/EP2016/058371 patent/WO2016166299A1/en not_active Ceased
- 2016-04-15 US US15/566,411 patent/US20180125994A1/en not_active Abandoned
- 2016-04-15 MX MX2017013154A patent/MX2017013154A/es unknown
- 2016-04-15 CA CA2981920A patent/CA2981920A1/en not_active Abandoned
- 2016-04-15 EP EP16716583.6A patent/EP3283118A1/en not_active Withdrawn
- 2016-04-15 KR KR1020177030351A patent/KR20170137115A/ko not_active Withdrawn
- 2016-04-15 JP JP2017553879A patent/JP2018511628A/ja active Pending
- 2016-04-15 BR BR112017022256A patent/BR112017022256A2/pt not_active Application Discontinuation
- 2016-04-15 CN CN201680022066.8A patent/CN107683146A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017022256A2 (pt) | 2018-07-31 |
| US20180125994A1 (en) | 2018-05-10 |
| JP2018511628A (ja) | 2018-04-26 |
| EP3283118A1 (en) | 2018-02-21 |
| CA2981920A1 (en) | 2016-10-20 |
| KR20170137115A (ko) | 2017-12-12 |
| AU2016249877A1 (en) | 2017-10-26 |
| GB201506393D0 (en) | 2015-05-27 |
| WO2016166299A1 (en) | 2016-10-20 |
| CN107683146A (zh) | 2018-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013154A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| ZA201706745B (en) | Site-specific antibody-drug conjugates | |
| MX2017013171A (es) | Conjugados anticuerpo-farmaco de sitio especifico. | |
| ZA201805336B (en) | Amanitin conjugates | |
| MX2016016515A (es) | Derivados de auristatina y conjugados de los mismos. | |
| MX2019010804A (es) | Compuestos de benzazepina, conjugados y usos de los mismos. | |
| ZA201903062B (en) | Amanitin antibody conjugates | |
| BR112016004242A2 (pt) | métodos para conjugação sítio-específica de anticorpos e composições | |
| ZA201903667B (en) | Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers | |
| CY1123525T1 (el) | Μορια δεσμευσης ειδικα για asct2 και χρησεις αυτων | |
| MX2016007865A (es) | Peptidos citotoxicos y conjugados de los mismos. | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| MX395142B (es) | Marcadores selectivamente desregulados en celulas t reguladoras, infiltrantes de tumores. | |
| MX2015005810A (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco. | |
| IN2015DN02577A (OSRAM) | ||
| WO2014134483A3 (en) | Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| ZA202001747B (en) | Psma-targeting amanitin conjugates | |
| MA39909A (fr) | Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer | |
| EA202091161A1 (ru) | Конъюгаты антител против cd22 с майтанзином, их комбинации и способы применения | |
| WO2018053552A3 (en) | Isoquinolidinobenzodiazepines | |
| IL272931A (en) | Peptide conjugates, conjugation process and their uses | |
| EP3775186A4 (en) | ECTONUCLEOTIDE PYROPHOSPHATE-PHOSPHODIESTERASE (ENPP) CONJUGATES AND THEIR USES | |
| BR112016010051A2 (pt) | ?conjugados de anticorpo-fármaco anti-efna4? | |
| WO2019121687A3 (en) | Immunotoxin conjugates for use in therapy |